The interplay of knowledge, motivation, and treatment response in medication adherence among patients with chronic myeloid leukemia treated with Imatinib

被引:0
作者
Omran, Mervat M. [1 ]
Ibrahim, Amel B. [2 ]
Abdelfattah, Raafat [3 ]
Moussa, Heba S. [4 ]
Shouman, Samia A. [1 ]
Hamza, Marwa S. [5 ]
机构
[1] Cairo Univ, NCI, Canc Biol Dept, Pharmacol Unit, Kasr Al Eini St, Cairo 11796, Egypt
[2] Zawia Univ, Fac Med, Dept Pharmacol, Az Zawiyah, Libya
[3] Cairo Univ, NCI, Med Oncol Dept, Cairo, Egypt
[4] Cairo Univ, NCI, Clin Pathol Dept, Cairo, Egypt
[5] British Univ Egypt, Fac Pharm, Clin Pharm Practice Dept, El Sherouk City, Cairo, Egypt
关键词
Imatinib mesylate; CML; adherence; trough; peak; CHRONIC MYELOGENOUS LEUKEMIA; CYTOGENETIC RESPONSES; TYROSINE KINASE; BLAST CRISIS; THERAPY; NONADHERENCE; OUTCOMES;
D O I
10.1080/10428194.2024.2403671
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic Myeloid Leukemia (CML) requires consistent medication adherence to Imatinib (IM) for optimal outcomes, however, adherence to oral chemotherapy is challenging. This observational study explores the relationship between patient knowledge, motivation, and adherence to IM therapy, and their collective impact on clinical outcomes. A prospective, observational study was conducted with 101 CML patients. The 6-Item Morisky Medication Adherence Scale (MMAS-6) was used to assess adherence, motivation, and knowledge levels. The study found that high motivation was significantly associated with lower BCR-ABL expression (p = 0.025). Patients with high knowledge and motivation had a 71% favorable response rate, compared to 0% in those with low knowledge and motivation (p = 0.01). As conclusion both patient motivation and knowledge are crucial for favorable treatment outcomes in CML. High levels of both significantly correlate with better clinical responses. Tailored interventions to enhance patient knowledge and motivation are essential.
引用
收藏
页码:123 / 130
页数:8
相关论文
共 50 条
  • [21] INFLUENCE OF LATE TREATMENT ON HOW CHRONIC MYELOID LEUKEMIA RESPONDS TO IMATINIB
    Costa Scerni, Ana Carolina
    Alvares, Leonardo Azevedo
    Beltrao, Ana Cristina
    Bentes, Ie Regina
    Azevedo, Tereza Cristina
    Bentes, Alessandra Quinto
    Rodrigues Lemos, Jose Alexandre
    CLINICS, 2009, 64 (08) : 731 - 734
  • [22] Treatment with Interferon alpha prior to discontinuation of Imatinib in patients with chronic myeloid leukemia
    Hardan, Izhar
    Stanevsky, Anfisa
    Volchek, Yuliya
    Tohami, Tali
    Amariglio, Ninette
    Trakhtenbrot, Luba
    Koren-Michowitz, Maya
    Shimoni, Avichai
    Nagler, Arnon
    CYTOKINE, 2012, 57 (02) : 290 - 293
  • [23] Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate
    Siti Mariam, Ismail
    Norhidayah, Ramli
    Zulaikha, Abu Bakar
    Nazihah, Mohd Yunus
    Rosline, Hassan
    Kausar, Ghazali Anis
    Sarina, Sulong
    Azlan, Husin
    Ankathil, Ravindran
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response
    Ferreira, Amanda Pifano Soares
    Seguro, Fernanda Salles
    Abdo, Andre Ramires Neder
    Santos, Fernanda Maria
    Maciel, Felipe Vieira Rodrigues
    Nardinelli, Luciana
    Giorgi, Ricardo Rodrigues
    Ruiz, Antonio Roberto Lancha
    Ferreira, Milton Pifano Soares
    Rego, Eduardo Magalhaes
    Rocha, Vanderson
    Bendit, Israel
    ANNALS OF HEMATOLOGY, 2023, 102 (07) : 1761 - 1771
  • [25] Prevalence of Anemia among Chronic Myeloid Leukemia Patients Treated with Imatinib: A Evidence-based Meta-analysis
    Singh, Avinash Kumar
    Kumar, Anoop
    Agrawal, Narendra
    Bhurani, Dinesh
    Ahmed, Rayaz
    Sharma, Manju
    CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2023, 18 (02) : 148 - 157
  • [26] Treatment of Chronic Phase Chronic Myeloid Leukemia with Imatinib
    Ganesan, Prasanth
    Rajendranath, Rejiv
    Kandakumar, Vignesh
    Sagar, Tenali Gnana
    INDIAN JOURNAL OF PEDIATRICS, 2015, 82 (03) : 235 - 239
  • [27] Adherence to tyrosine kinase inhibitors among adult chronic myeloid leukemia patients in a Malaysia hospital
    Lee, P. M.
    Chang, C. T.
    Yusoff, Z. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (01) : 46 - 54
  • [28] Suboptimal response in chronic myeloid leukemia patients treated with imatinib: Early identification and new therapeutic challenges
    Breccia, Massimo
    Alimena, Giuliana
    CANCER LETTERS, 2012, 325 (01) : 18 - 25
  • [29] Imatinib in the treatment of chronic myeloid leukemia in Morocco
    Dakkoune, Mariem
    Qachouh, Meryem
    Zoukal, Sofia
    Hassoune, Samira
    Khoubila, Nisrine
    Cherkaoui, Siham
    Lamchahab, Mouna
    Rachid, Mohamed
    Madani, Abdellah
    Quessar, Asmaa
    BULLETIN DU CANCER, 2020, 107 (09) : 861 - 866
  • [30] Preliminary Validation of Self-assessment Tool to Measure Imatinib Adherence in Patients with Chronic Myeloid Leukemia
    Daouphars, Mikael
    Ouvry, Marine
    Lenain, Pascal
    Rouvet, Jean
    Jardin, Fabrice
    Bubenheim, Michael
    Varin, Remi
    PHARMACOTHERAPY, 2013, 33 (02): : 152 - 156